Biogen Idec Inc (NASDAQ:BIIB) and ISIS Pharmaceuticals, Inc (NASDAQ:ISIS) reported on Friday that they would work together to make a treatment for the most ordinary type of muscular dystrophy in adults.
The Weston, Massachusetts based Biogen decided to pay Isis $12 million upfront. The Carlsbad, California based corporation could get $59 million in development milestone payments and one more $200 million in license charges and regulatory milestone payments. Isis would also get royalty payments of above 10% if the drug is approved.
Isis would be responsible for identifying a drug candidate for further development, and it would be accountable for development through mid-stage clinical testing.
Shifting readers focus to broader market, let’s consider market performance of other stocks that significantly affect same sector. Amgen, Inc. (NASDAQ:AMGN) increased +2.09% to settle at $72.91, Elan Corporation, plc (ADR) (NYSE:ELN) moved up +1.60% to end at $14.59 while Pfizer Inc. (NYSE:PFE) jumped +2.09% to finish on Friday at $23.00.
Biogen Idec Inc. (NASDAQ:BIIB) on June 29, 2012 increased +3.05% to the closing price of $144.38. The overall volume in the last trading session was 1.49 million shares. Its fifty two week range was $83.83-$144.38. The total market capitalization remained $34.59 billion.
BIIB is ahead its 52 week low with +72.23% and going forward from its 52 week high price with +0.45%. BIIB last month stock price volatility remained 2.07%. In its share capital BIIB has 239.56 million outstanding shares among them 237.17 million shares have been floated in market exchange. BIIB stock institutional ownership remained 94.87% while insider ownership included 0.12%.
The stock price of BIIB is moving forward from its 20 days moving average with +5.14% and remote positively from 50 days moving average with +7.60%. BIIB current year earnings per share experienced an addition with +27.93% while its current quarter performance remained +14.59%. Company’s beta coefficient included 0.84. Beta factors measures the amount of market risk associated with market trade.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL
